logo
Colorectal Cancer Canada (CCC) advocates to lower the age for colorectal cancer screening to 45 for Canadians at average risk Français

Colorectal Cancer Canada (CCC) advocates to lower the age for colorectal cancer screening to 45 for Canadians at average risk Français

Cision Canada17-06-2025
MONTREAL, June 17, 2025 /CNW/ - Colorectal Cancer Canada, through its Never Too Young (N2Y) initiative, is launching an advocacy campaign to lower the colorectal cancer screening age to 45 for average-risk Canadians and to raise awareness about the signs, symptoms, and risk reduction strategies—particularly targeting individuals under 50.
"Our objective is to ensure that young Canadians do not ignore the signs and symptoms just because of their age and that they are aware of their family medical history and risk level, as we call on our provincial and territorial health ministries to lower the screening age for colorectal cancer throughout the country to 45," said Mr. Barry D. Stein, President and CEO of Colorectal Cancer Canada.
Colorectal Cancer doesn't care how old you are
Colorectal cancer is often mistakenly viewed as "an old person's disease". The reality is that early-onset colorectal cancer (EOCRC), which arises in individuals below the age of 50, is on the rise, while Canada is experiencing a decline in colorectal cancer incidence and mortality in people aged 50 and over.
While most new cases still occur in those aged 50 and older, Canadians born after 1980 are 2 to 2.5 times more likely to be diagnosed with colorectal cancer before age 50 compared to earlier generations. Furthermore, younger adults tend to be diagnosed with CRC at more advanced stages, posing unique challenges for prognosis and treatment
Why should we lower the age to 45 years old?
In Canada, colorectal cancer screening for individuals at average-risk* is currently offered between the ages of 50 and 74 across all provinces and territories. However, with the growing incidence of EOCRC among younger adults, Colorectal Cancer Canada is calling upon all provinces and territories to immediately lower the screening age for colorectal cancer to 45, similarly to countries like the United States and Australia
An average-risk person is someone between 50 and 74 years old who has no symptoms and no personal or family history of colorectal cancer, certain polyps, genetic conditions like Lynch syndrome, or inflammatory bowel diseases such as Crohn's or colitis.
In 2018, the U.S. Preventive Services Task Force updated its guidelines to include individuals aged 45–49, following evidence-based recommendations from the American Cancer Society. Similarly, in July 2024, the Australian government reduced the starting age for its National Bowel Cancer Screening Program from 50 to 45.
"Based on a 2023 microsimulation, initiating screening at age 45 resulted in a net 12,188 fewer CRC cases, and 5,261 fewer CRC deaths. We believe that by lowering the screening age, we can prevent many more cancers and ultimately save thousands of lives in Canada", Barry D. Stein concluded.
Colorectal cancer is one of the most preventable, treatable and beatable cancers when it is caught in the early stages resulting in less invasive treatment, better outcomes, and lower treatment costs for health systems, patients, caregivers, and their loved ones.
About Colorectal Cancer Canada
Colorectal Cancer Canada (CCC) is Canada's national colorectal cancer patient led non-for-profit organization. Since 1998, it has been dedicated to colorectal cancer awareness and education, supporting patients and caregivers, and advocating on their behalf. CCC's mission is to reduce the incidence and mortality of colorectal cancer in Canada and to improve the quality of life for patients, their families and caregivers.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Public advisory - Unlicensed Mitolux UV sunlamps for Vitamin D may pose health risks Français
Public advisory - Unlicensed Mitolux UV sunlamps for Vitamin D may pose health risks Français

Cision Canada

time2 hours ago

  • Cision Canada

Public advisory - Unlicensed Mitolux UV sunlamps for Vitamin D may pose health risks Français

, /CNW/ - Summary Product: Unlicensed ultraviolet (UV) sunlamps Issue: Health products – Unauthorized product; Product safety What to do: Do not use unlicensed Mitolux UV sunlamps. Consult a health care professional if you have used any of these sunlamps and have concerns about your health. Check whether medical devices have been licensed for sale by searching Health Canada's Medical Devices Active Licence Listing. Report any health product-related side effects or complaints to Health Canada. Affected products Issue Health Canada is warning consumers that unlicensed ultraviolet (UV) sunlamps sold by Mitolux may pose health risks due to excessive and unsafe ultraviolet B (UVB) radiation levels. The devices are marketed to be a reliable source of natural Vitamin D. Too much exposure to UVB radiation from using Mitolux UV sunlamps can cause: skin reactions and burns eye damage premature skin aging skin cancer with repeated exposure It is illegal to advertise for sale, import for sale, or sell medical devices in Canada without appropriate licensing under the Medical Devices Regulations. Health Canada is asking companies that sell Mitolux UV sunlamps to immediately stop selling them. Should additional safety concerns be identified, Health Canada will take appropriate action to protect public health and safety, including communicating updates, if needed. What you should do

BTL Expands EMFACE® Indications with New FDA Clearance for TMJ Dysfunction
BTL Expands EMFACE® Indications with New FDA Clearance for TMJ Dysfunction

Cision Canada

time4 hours ago

  • Cision Canada

BTL Expands EMFACE® Indications with New FDA Clearance for TMJ Dysfunction

BOSTON, Aug. 13, 2025 /CNW/ -- BTL Industries, a global leader in medical and wellness technologies, has expanded the FDA-cleared applications of its EMFACE® platform with a new indication for the treatment of temporomandibular joint (TMJ) dysfunction. EMFACE® is now cleared by the FDA for the relief of symptoms associated with muscle spasm, treatment of TMJ dysfunction and associated pain, muscle re-education, increased local blood flow, and the maintenance or improvement of mandibular range of motion. Developed through years of research and engineering, EMFACE combines synchronized radiofrequency and HIFES® technology for facial muscle stimulation, delivering relief without surgery, injections, or medication. "EMFACE is an established technology platform with multiple FDA-cleared uses," said David Chmel, CEO of BTL Industries. "This new indication allows dental, oral health, and wellness providers to address TMJ dysfunction within its approved uses, expanding the benefits of EMFACE to more patients." "TMJ dysfunction impacts more than the jaw — it affects quality of life," said Shireen Dhanani, DMD, Leesburg, FL. "With EMFACE, we can now offer an accessible, non-invasive option that not only helps patients find relief and functional improvement, but also expands the scope of dental care." BTL continues to redefine what's possible in facial care and wellness, bringing science-backed technologies like EMFACE into new areas of medicine to improve lives and advance patient care worldwide. For more information about EMFACE, visit www. About BTL Industries Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. Operating in over 90 countries, BTL holds more than 200 patents and employs over 500 R&D engineers dedicated to advancing medical treatments through technology and science. Its product portfolio includes EMSCULPT NEO®, EMFACE®, EXION™, EXOMIND™, EMSELLA®, and others.

New Study Demonstrates Superiority of EggNest™ Complete Radiation Protection System in Comprehensive Protection for the Entire Interventional Team
New Study Demonstrates Superiority of EggNest™ Complete Radiation Protection System in Comprehensive Protection for the Entire Interventional Team

Cision Canada

time5 hours ago

  • Cision Canada

New Study Demonstrates Superiority of EggNest™ Complete Radiation Protection System in Comprehensive Protection for the Entire Interventional Team

MINNEAPOLIS, Aug. 13, 2025 /CNW/ -- A recent study published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) highlights the effectiveness of the EggNest™ Complete radiation shielding system, demonstrating its superior ability to protect all personnel in the catheterization lab from scatter radiation. The findings show that while other next-generation systems offer protection for the primary operator and assistant, the EggNest™ Complete system provides significant protection for the entire interventional team. The study, titled "Comparative Effectiveness of 2 Next-Generation Scatter Radiation Shielding Systems," compared the EggNest™ Complete system with the Rampart IC system and a no-shielding condition using an anthropomorphic phantom. The results showed that both the EggNest™ Complete and Rampart IC systems significantly reduced radiation exposure for the operator and assistant positions compared to no shielding. However, the EggNest™ Complete system provided additional significant protection for staff at the head of the bed and the nursing positions, a benefit not observed with the Rampart IC system. "From the beginning, Egg Medical has had three guiding principles: we need to protect the entire team from scatter radiation, we can't interfere with workflow or patient access, and the reduction in radiation exposure must be nearly complete. The study by Riley et al shows very clearly that the EggNest Complete system dramatically reduces radiation exposure for everyone in the room, and that the operator and assistant are almost completely protected. That is a marked improvement to safety for everyone who works in x-ray guided procedures," said Dr. Robert Wilson, CEO of Egg Medical. The study's authors note that interventional cardiology procedures expose healthcare professionals to prolonged ionizing radiation, which poses significant health risks including heightened rates of malignancy, cataracts, and orthopedic injuries. Traditional lead aprons, while offering some protection, are heavy (up to 25 pounds) and can lead to musculoskeletal injuries. A recent SCAI survey found that 66% of operators reported musculoskeletal pain attributed to their time in the cardiac catheterization laboratory. "It's a community effort to bring the issue of healthcare worker safety to the forefront of our industry. We deserve the same level of protection we strive to give to patients. This study highlights that Egg Medical's EggNest Complete System sets a new standard for what ALARA (As Low As Reasonably Achievable) means today," said Robert Riley, MD, a co-author of the study. The study's findings indicate that a comprehensive shielding system like EggNest™ Complete is crucial for ensuring the safety of all interventional lab personnel, including operators, assistants, nurses, and other staff. This is particularly important for complex procedures where staff may be positioned in areas with limited traditional shielding and higher cumulative exposure. The authors of a separate commentary on the study commended the findings, emphasizing that these results align with the Society for Cardiovascular Angiography & Interventions' mission to advance occupational safety and are essential for sustaining the interventional cardiology workforce. Comparative Effectiveness of 2 Next-Generation Scatter Radiation Shielding Systems. Stephen Kidd, MD, Robert F. Riley, MD, MS, Juliette Power, MD, Brian Stegman, MD, Thom G. Dahle, MD. Division of Cardiology, Overlake Medical Center, Bellevue, Washington. Division of Cardiology, St. Cloud Hospital, St. Cloud, Minnesota. Journal of the Society for Cardiovascular Angiography & Interventions (2025), doi: About Egg Medical Egg Medical is a global leader in radiation protection technologies. Headquartered in Minnesota, the company was founded with the goal to reduce the scatter radiation exposure of physicians, surgeons, nurses, technicians and others who use x-ray imaging to perform life-saving diagnostic and therapeutic procedures for patients. More information about Egg Medical is available at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store